The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.
Antonio Llombart-Cussac
Consultant or Advisory Role - Roche
Honoraria - Roche
Xavier B. Pivot
Consultant or Advisory Role - Roche
Honoraria - Roche
Laura Biganzoli
No relevant relationships to disclose
Hernan Cortes-Funes
No relevant relationships to disclose
Kathleen I. Pritchard
No relevant relationships to disclose
Jean-Yves Pierga
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Ian E. Smith
No relevant relationships to disclose
Christoph Thomssen
Honoraria - Roche
Other Remuneration - Roche
Gemma Palacios
Employment or Leadership Position - Roche
Stefanie Srock
Employment or Leadership Position - Roche
Stock Ownership - Roche
Miguel Sampayo
No relevant relationships to disclose
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche